IBM Watson Health is now collaborating with Illumina, a biotechnology company focused on genome sequencing solutions.
Through this partnership, Illumina will integrate Watson for Genomics into its BaseSpace Sequence Hub and tumor sequencing process in an effort to standardize genomic data interpretation. Watson for Genomics will read genetic alteration files alongside professional guidelines, medical literature and clinical trials to produce a comprehensive report for researchers.
The Watson for Genomics and Illumina integration will take place in early 2017.